All you need to know about Biologics and Biosimilars

A Patient-centric Case-based Approach for Pharmacists

A patient has been prescribed a biosimilar for RA.
HOW DO YOU DISCUSS THIS NEW TREATMENT?

Faculty and Video Experts

  • Dr. Alan Low
  • Mr. Aaron Sihota
  • Mr. Gabriel Torani
  • Ms. Carolyn Whiskin

Special Collaboration Video Expert
Denis Choquette, MD, Rheumatologist

Learning Objectives

After attending this session, participants will be able to:

  • Describe the process by which biosimilars are approved and regulated by Health Canada
  • Explain key data on biosimilars used in rheumatology
  • Apply experiences and practical tips provided by experts to improve communication with patients on the use of biosimilars
  • Use the acquired knowledge to educate patients and address their questions on the use of biosimilars with confidence

CCCEP File No. 1177-2018-2619-I-P
The Canadian Council on Continuing Education in Pharmacy has accredited this program for 1.5 CEUs.
 

Registration Information

This course is complimentary. Click on the link below and entire the access code to start the webinar.

Access code: biosimilar